Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Karuna Therapeutics Inc (NQ: KRTX )

220.17 +0.36 (+0.16%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 242,808
Open 218.91
Bid (Size) 210.23 (1)
Ask (Size) 230.17 (1)
Prev. Close 219.81
Today's Range 217.65 - 221.47
52wk Range 93.47 - 278.25
Shares Outstanding 37,443,954
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Karuna Therapeutics to Present Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the American Society of Clinical Psychopharmacology Annual Meeting
From Karuna Therapeutics, Inc.
Via Business Wire
The Latest Analyst Ratings for Karuna Therapeutics
 
Via Benzinga

Performance

YTD
+13.97%
+13.97%
1 Month
+7.34%
+7.34%
3 Month
+11.59%
+11.59%
6 Month
-1.55%
-1.55%
1 Year
+111.05%
+111.05%

More News

Read More
Karuna Therapeutics's Return On Capital Employed Overview
Via Benzinga
Royalty Pharma Reaffirms FY23 Guidance Post Mixed Q1 Performance
Via Benzinga
Karuna Therapeutics Reports First Quarter 2023 Financial Results and Provides General Business Updates
From Karuna Therapeutics, Inc.
Via Business Wire
3 Biotech Buyout Targets to Watch
Via The Motley Fool
Why Shares of Karuna Therapeutics Were Up Wednesday
Via The Motley Fool
Karuna Therapeutics to Present at Upcoming Investor Conferences
From Karuna Therapeutics, Inc.
Via Business Wire
PureTech Health FY22 Revenue Declines 10.2% YoY, Here Are The Details
Via Benzinga
Karuna Therapeutics to Announce First Quarter 2023 Financial Results and Provide General Business Update on Thursday, May 4, 2023
From Karuna Therapeutics, Inc.
Via Business Wire
Karuna Therapeutics Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
From Karuna Therapeutics, Inc.
Via Business Wire
Analyst Expectations for Karuna Therapeutics's Future
Via Benzinga
Karuna Surges To Three-Month High On Another Win In Schizophrenia
Via Investor's Business Daily
Karuna Therapeutics to Present at the Stifel 2023 CNS Days
From Karuna Therapeutics, Inc.
Via Business Wire
Why Edible Garden Shares Are Trading Lower By Over 26%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Travelzoo, Semler Scientific, Ollie's Bargain Outlet And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Karuna Therapeutics Announces Pricing of Public Offering of Common Stock
From Karuna Therapeutics, Inc.
Via Business Wire
Why Citi Trends Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Karuna Therapeutics Announces Proposed Public Offering of Common Stock
From Karuna Therapeutics, Inc.
Via Business Wire
ENPH Stock Price Prediction: Can Enphase Energy Really Hit $225?
Via InvestorPlace
UBS Stock Price Prediction: Why This Analyst Says UBS Is a ‘Buy’
Via InvestorPlace
Karuna Therapeutics Says It One Step Closer To Potential Treatment Option After Encouraging Schizophrenia Data
Via Benzinga
Why Is Karuna Therapeutics (KRTX) Stock Moving Today?
Via InvestorPlace
Zai Lab Partner Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-3 Trial of KarXT in Schizophrenia
From Zai Lab Limited
Via GlobeNewswire
Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-3 Trial of KarXT in Schizophrenia
From Karuna Therapeutics, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.